Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to ...

This promising strategy could slow or halt Huntington's disease progression at the root of its genetic cause. "Targeting MSH3 is exciting not only because it's directly involved in the CAG repeat ...

Huntington disease (HD) is a progressive and fatal neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene (HTT). In a recent study, Bunting et al. use an antisense ...

At birth, people who carry a string of more than 40 CAG repeats within the first exon of the huntingtin gene are all but destined to develop Huntington’s disease. Yet, recent studies are converging on ...

Ranum, PhD Day: Wednesday, February 26, 2025 Abstract Title: Targeting MSH3 for Huntington’s Disease: Preclinical Validation of AAV-DB-3-miRNA to Prevent Somatic CAG Repeat Expansion Presenter ...

Several recent high-profile papers provide unequivocal support for the development of treatments targeting somatic CAG repeat ... triplet repeat diseases, including Huntington's Disease.

HDBuzz reported live updates on Bluesky from the 2025 HD Therapeutics Conference. Read on for coverage of Day 2. #CHDI2025 ...

So during this Sleep Awareness Week, March 9th through 15th, we’re sounding the alarm on sleep issues related to Huntington’s disease (HD ... Based on age and CAG repeat length, around a third of the ...